课题基金 / 基金详情

ACTG 316, V 1--NEVIRAPINE VERSUS NEVIRAPINE PLACEBO IN PREGNANT HIV WOMEN

ACTG 316, V 1--NEVIRAPINE VERSUS NEVIRAPINE PLACEBO IN PREGNANT HIV WOMEN
ACTG 316,V 1--奈韦拉平与奈韦拉平安慰剂在艾滋病毒孕妇中的比较
批准号:
6264928
负责人:
MARK H MIROCHNICK
金额:
$3.05万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

MARK H MIROCHNICK的其他基金

相似基金

相关文献

中文摘要
翻译
这项III期随机双盲临床试验旨在确定在分娩过程中给母亲和出生后48-72小时的婴儿服用奈韦拉平是否可以降低产前传播的风险。预计胎龄&32周的HIV-1感染孕妇将被登记。通过接受怀孕晚期的妇女,这项研究与目前开放的研究ACTG185并不冲突,ACTG185要求妇女在怀孕30周前登记。(ACTG 316,V.1)
英文摘要
This phase III randomized, double-blind clinical trial is designed to determine if Nevirapine, given to the mother during active labor and to the infant 48-72 hours after birth, can reduce the risk of prenatal transmission. HIV-1 infected pregnant women with estimated gestational age >-32 weeks will be enrolled. By accepting women who present late in pregnancy, this study does not conflict with the currnetly open study ACTG185, which requires enrollment of women by 30 weeks of gestation. (ACTG 316, V. 1)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Safety Pharmacokinetics & Efficacy of Artemether & Lumefantrine in Pregnant Women
  • 批准号:
    7360186
  • 项目类别:
  • 资助金额:
    $12.32万
  • 财政年份:
    2008
  • 负责人:
    MARK H MIROCHNICK
  • 依托单位:
PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20)
  • 批准号:
    7606238
  • 项目类别:
  • 资助金额:
    $1.4万
  • 财政年份:
    2007
  • 负责人:
    MARK H MIROCHNICK
  • 依托单位:
PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV INFECTED WOMEN
  • 批准号:
    7606254
  • 项目类别:
  • 资助金额:
    $0.11万
  • 财政年份:
    2007
  • 负责人:
    MARK H MIROCHNICK
  • 依托单位:
ANTIRETROVIRAL DRUGS DURING PREGNANCY, SUBSTUDY OF PACTG P1025
  • 批准号:
    7606233
  • 项目类别:
  • 资助金额:
    $0.22万
  • 财政年份:
    2007
  • 负责人:
    MARK H MIROCHNICK
  • 依托单位:
海外基金